SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-005155
Filing Date
2023-01-25
Accepted
2023-01-25 16:44:39
Documents
19
Period of Report
2023-01-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea172170-8k_jasper.htm   iXBRL 8-K 38638
2 UNDERWRITING AGREEMENT, DATED AS OF JANUARY 25, 2023, BY AND BETWEEN JASPER THER ea172170ex1-1_jasper.htm EX-1.1 234250
3 OPINION OF PAUL HASTINGS LLP ea172170ex5-1_jasper.htm EX-5.1 7404
4 PRESS RELEASE, DATED JANUARY 25, 2023 ea172170ex99-1_jasper.htm EX-99.1 11273
9 GRAPHIC ex5-1_001.jpg GRAPHIC 3339
10 GRAPHIC ex5-1_002.jpg GRAPHIC 3581
11 GRAPHIC ex99-1_001.jpg GRAPHIC 4900
  Complete submission text file 0001213900-23-005155.txt   597652

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE jspr-20230125.xsd EX-101.SCH 4133
6 XBRL DEFINITION FILE jspr-20230125_def.xml EX-101.DEF 26833
7 XBRL LABEL FILE jspr-20230125_lab.xml EX-101.LAB 37093
8 XBRL PRESENTATION FILE jspr-20230125_pre.xml EX-101.PRE 25457
13 EXTRACTED XBRL INSTANCE DOCUMENT ea172170-8k_jasper_htm.xml XML 5873
Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Filer) CIK: 0001788028 (see all company filings)

IRS No.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39138 | Film No.: 23552933
SIC: 2836 Biological Products, (No Diagnostic Substances)